Edgar D Copado-Villagrana

Prof. Edgar D Copado-Villagrana

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
Edgar D Copado-VillagranaEdgar D Copado-Villagrana
Edgar D Copado-Villagrana
ILIlsy Xitlaly Duarte López
Ilsy Xitlaly Duarte López
ACArturo Calderón-Flores
Arturo Calderón-Flores
ILIsidro Loera-Robles
Isidro Loera-Robles
OVOliver Viera-Segura
Oliver Viera-Segura
Nora A. FierroNora A. Fierro
Nora A. Fierro
The global distribution of hepatitis E virus (HEV) is attributed to its capacity to spread through several routes of transmission; hemodialysis has gained increased amounts of attention in recent years. Although Mexico is considered a hyperendemic region for hepatitis E, no HEV surveillance is performed in the country. The frequency of HEV in hemodialysis (HD) patients has not been determined. Herein, we conducted a cross-sectional single-center analytical study including 67 serum samples from HD patients. Anti-HEV IgG and IgM antibodies and the viral genome were determined; partial regions within the HEV genome were sequenced for further phylogenetic analysis. Globally, 14.9% of the tested patients exhibited reactivity for IgG antibodies against HEV, and none showed reactivity to IgM. A total of 5.9% of the samples showed HEV genome amplification, and sequencing confirmed the identity of genotype 3; subsequent analysis of positive cases revealed two acute cases and chronic hepatitis E infection in one patient. Notably, the chronic patient was negative for anti-HEV IgG antibodies. Our findings highlight the importance of viral genome testing in HD patients and the need to establish guidelines for HEV detection in Mexico.

26 April 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
OVOliver Viera-Segura
Oliver Viera-Segura
ILIlsy Xitlaly Duarte López
Ilsy Xitlaly Duarte López
ILIsidro Loera-Robles
Isidro Loera-Robles
NRNorberto Singh Rios
Norberto Singh Rios
ACArturo Calderón-Flores
Arturo Calderón-Flores
Nora A. FierroNora A. Fierro
Nora A. Fierro
Hepatitis E virus (HEV), the causative agent of hepatitis E, is the leading cause of acute viral hepatitis worldwide; under immunosuppression, infection can lead to chronic liver disease. Furthermore, extrahepatic manifestations, particularly renal manifestations, are frequently associated with infection. This is important considering the global burden of chronic kidney disease (CKD). However, the study of chronic hepatitis E has been limited to liver disease, and its definition with respect to renal disease is still incomplete. Recently, through a protocol aimed at identifying HEV seroprevalence in a cohort of patients on hemodialysis, we incidentally identified HEV RNA in a patient with a history of alcoholism, diabetes mellitus, and essential systemic hypertension. In this study, we aimed to follow up this case to characterize hepatitis E in the context of CKD. Notably, we identified the development of chronic HEV genotype 3 infection without seroconversion or evidence of liver damage. Moreover, apparent immunocompetence was identified in the patient. Considering that HEV is still neglected in numerous countries and that it is not included in the differential diagnosis of kidney disease, our findings support the need to consider HEV infection in patients with renal disease, even in the absence of liver deterioration.

3 February 2026 in Virology Journal
Verified
Journal Article
Open access
PDF file
VGVictor M. Gudiño-Hernández
Victor M. Gudiño-Hernández
MVMauricio Vázquez-Pichardo
Mauricio Vázquez-Pichardo
OVOliver Viera-Segura
Oliver Viera-Segura
NFNora A. Fierro
Nora A. Fierro
YTYanelli Torres-Olmos
Yanelli Torres-Olmos
Edgar D Copado-VillagranaEdgar D Copado-Villagrana
Edgar D Copado-Villagrana
West Nile virus (WNV) is primarily transmitted by the bite of Culex mosquitoes, but other mechanisms, such as blood transfusion, have also been described.

1 July 2024
Verified
Journal Article
Open access
JPJesús Antonio Pérez-Mercado
Jesús Antonio Pérez-Mercado
DGDiana Lizeth Gallegos-Durazo
Diana Lizeth Gallegos-Durazo
JHJorge Rafael Hernández-Donnadieu
Jorge Rafael Hernández-Donnadieu
Edgar D Copado-VillagranaEdgar D Copado-Villagrana
Edgar D Copado-Villagrana
Hepatitis C Virus (HCV) infection represents a global public health problem, but in Mexico, the Ministry of Health through the National Epidemiological Surveillance System (SINAVE) only reports the distribution of incident cases by state, sex and epidemiological week. To determine the seroprevalence and factors associated with HCV in beneficiaries of a Family Medicine Unit of the Mexican Social Security Institute (IMSS) in the city of Nogales, Sonora, located on the border between Mexico and the United States. Cross-sectional study that included 145 beneficiaries with rapid HCV antibody test results. Information on risk factors was obtained through direct questioning. To compare groups of reactive and non-reactive patients, Fisher's Exact Test was used and a Logistic Regression model to determine Odds Ratio (OR) values. A P value <0.05 was considered statistically significant. A seroprevalence of 2.8% (95%CI: 0.8 - 6.9) was determined and through the logistic regression model it was found that the history of transfusions (OR: 151.2, 95%CI: 5.9 - 3.858.0) and the use of intranasal drugs (OR: 20.81, 95%CI: 1.3 - 331.3) increase the risk of infection. The seroprevalence of HCV in Nogales is higher than that of the rest of Mexico. Recent studies establish a history of transfusion as a risk factor, but few have explored intranasal drug use.